Dublin, Oct. 02, 2024 - A new report analyzing trends in Adoptive Cell Therapy (ACT) clinical trials reveals significant growth and shifts in the landscape. The report, which examines trials up to May 1, 2024, highlights an increasing number of ACT trials, offering a deeper understanding of factors such as sponsor type, therapy areas, location, and trial phase.
Ongoing Trials and Novel Therapies
The analysis indicates that 42% of all ACT trials are currently ongoing. This high percentage suggests a potential surge of new adoptive cell therapies in the coming years. Given that the first CAR-T therapies were commercialized just seven years ago, the field is still relatively new. The report also points out the inherent challenges in advancing these therapies from trial stages to completion.
CAR-T Dominance in Immunotherapy
CAR-T treatments continue to be a major focus in the realm of T cell immunotherapy. According to the report, CAR-T therapies account for 83% of all T cell immunotherapy trials and 55% of all adoptive cell therapy trials, underscoring their significance in the field.
Regional Distribution
A notable shift in regional dominance has occurred, with the Asia-Pacific (APAC) region surpassing North America in the number of ACT trials since 2016. APAC has maintained its leading position, indicating a growing interest and investment in cell therapy research and development in the region.
Key Report Findings
The report segments and analyzes ACT trials by various factors, including phase, single versus multinational status, geography, sponsor type (industry vs. non-industry), therapy area, indication, top sponsors, drug type, and the use of decentralized clinical trial components. It also examines the reasons behind the increase in psychedelic clinical trials and identifies trends, breaks down trials by sponsor type, and describes the leading drugs used in these trials.
Figures within the report illustrate the distribution of trials by year, regional distribution, top countries, and trial phase. Additionally, the report identifies top industry and non-industry sponsors, reasons for trial terminations, and the use of virtual components in clinical trials. It also highlights the top indications in ACT clinical trials by phase and provides a breakdown of trial types and statuses.
